A Phase 3, Open-Label, Multi-Center Trial to Evaluate the Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in
Clinical Trial Grant
Administered By
Neurology, Neuromuscular Disease
Awarded By
Revance Therapeutics Inc.
Start Date
March 14, 2019
End Date
December 31, 2021
Administered By
Neurology, Neuromuscular Disease
Awarded By
Revance Therapeutics Inc.
Start Date
March 14, 2019
End Date
December 31, 2021